Extension Of Receiving Antiviral Drugs Reduces The Risk Of Lung Rejection After Transplantation

Extension Of Receiving Antiviral Drugs Reduces The Risk Of Lung Rejection After Transplantation.


Extended antiviral care after a lung shift may advise prevent dangerous complications and organ rejection, a new study from Duke University Medical Center shows. A unexceptional cause of infection in lung transplant recipients is cytomegalovirus (CMV), which often causes yielding effects but can be life-threatening for transplant patients. Standard preventive therapy involves taking the opiate valganciclovir (Valcyte) for up to three months new mexico. But even with this treatment, most lung transplant patients come to light CMV infections within a year.



The Duke study included 136 patients who completed three months of voiced valganciclovir and then received either an additional nine months of placebo (66 patients) or an additional nine months of pronounced valganciclovir (70 patients). Since it was a double-blind, placebo-controlled randomized study, researchers compared two groups of randomly selected patients at 11 bizarre centers (one set of which received the additional medication and a control order that received the placebo, with neither the researchers nor the participants knowing who was in the control group) more. Researchers found that CMV infection occurred in 10 percent of the extended curing group, compared to 64 percent of the placebo group.



Pneumonia caused by CMV virus occurred in 4 percent of the extended-treatment assort and in 32 percent of the placebo group. "We found that 1 year of verbal valganciclovir was extremely effectual and led to a dramatic reduction in the rate of CMV infection and disease," Dr Scott Palmer, regulated director of the Lung Transplant Program at Duke University Medical Center, said in a university despatch release. Potential side effects of valganciclovir include nausea, diarrhea, anemia and other blood disorders, retinal detachment, headache, fever, vomiting, bonkers changes and other problems.



However, the over "showed that there was no increased or added toxicity with the extended course of treatment. In addition, the mug up examined viral resistance mutations and demonstrated that extended therapy did not protagonist to increased drug resistance, a potential concern with longer courses of treatment" resources. The study, published in the June 15 flow of the Annals of Internal Medicine, was funded by Roche Pharmaceuticals, which makes Valcyte.

tag : patients placebo valganciclovir extended transplant percent months group study

Post a comment

Private comment

Профиль

alejandrafalto

Author:alejandrafalto
Dr. Alejandra Falto

Новые записи
Новые комментарии
Новые трэкбэки
Архив по месяцам
Категории
Форма поиска
RSS ссылка
Ссылки
Формуляр приглашения в блог-друзья

Добавить автора в блог-друзья